Every strategy review process begins with the same data: performance against current customers, competitive position in current markets, satisfaction scores from current users. The information is accurate and structurally incomplete. It maps the territory that is already occupied and tells organizations how to compete within it more effectively. It is almost entirely silent about the territory that is not occupied — the people who are not currently using any offering in the space and whose entry into the market would create new demand rather than redistribute existing demand.
Kim and Mauborgne's Blue Ocean Strategy research identifies this orientation as one of the most persistent strategic traps: organizations that are "customer-led" in the narrow sense of focusing on current customers end up improving their offering for a shrinking competitive pool while leaving vastly larger untapped demand unaddressed. The instinct is defensible — serve the people you already have better. The strategic cost is that the largest opportunity remains systematically invisible.
What the data says about where value actually comes from
The profit differential is not explained by scale — the companies creating new market space were not necessarily larger investments. It is explained by the absence of direct competition. When an organization creates an offering that addresses a need no existing product or service is meeting — for people who are currently outside the market entirely — it is not dividing existing demand with competitors. It is creating new demand in space it temporarily owns.
The framework Kim and Mauborgne use to structure the noncustomer analysis identifies three distinct tiers. The first tier consists of people at the edge of the current market who are using the existing offering but would leave if a better alternative appeared. They are already dissatisfied; the question is what dissatisfies them. The second tier consists of people who have consciously refused the existing offerings — they are aware of what is available and have decided it does not work for them. Their refusal is a diagnostic: what specific barrier or failure is preventing their entry? The third tier consists of people who have never been considered potential customers at all — whose need exists but has never been framed in terms the current market addresses.
What this looks like in practice
Cirque du Soleil's founding is the canonical example. The traditional circus market in the late 1980s was shrinking — declining attendance, increasing animal welfare concerns, compressed margins from competition. The strategic logic for any operator in the space pointed inward: reduce costs, retain the most profitable acts, compete more aggressively for a declining pool of circus-goers. Cirque did the opposite. It identified a large pool of noncustomers — adults and corporate clients who had stopped attending the circus as children and would never return to it in its existing form — and asked what those people actually wanted from a live performance experience. The answer produced an offering that combined the athleticism of circus with the narrative of theatre and the production values of opera. It competed for nobody's market share because no market for it yet existed.
Novo Nordisk's transformation of insulin delivery followed the same structural logic. The existing insulin market was organized around doctors as the primary customer — the prescribing decision-maker whose preferences shaped product design and commercial strategy. The patients who administered insulin daily were present in the system but not consulted about their experience of using it. When Novo Nordisk shifted its focus to the patient as the primary design audience — a noncustomer of the attention the market had been paying — the result was the NovoPen, a delivery format that made insulin administration dramatically less disruptive to daily life. Market share followed because patient preference, once addressed, influenced prescribing.
The question most strategy sessions never ask
In life sciences, the noncustomers are often the most important actors in the system and the least consulted in strategy development. Payers who are not yet engaged with a therapeutic category. Patient communities whose adoption patterns will determine whether a drug achieves real-world efficacy. Pathologists whose workflow changes are the prerequisite for a biomarker-based therapy to function at scale. These are not peripheral stakeholders. They are the people whose entry into the strategy — as active participants, not communications targets — determines whether the launch succeeds.
In government, the noncustomers of most policy and programme design are the communities most affected by the problem the programme is trying to address — communities whose tacit knowledge of the constraint, the workaround, and the actual barrier is essential to designing an intervention that works. They are rarely in the room when the strategy is built. They experience the output.
The noncustomer question belongs in every strategy review, asked before the data on current performance is reviewed: who is not in this market, and what would it take to bring them in? The answer is almost always more strategically significant than the answer to the question of how to serve existing customers more effectively.